Molecular Associations Required for Signalling VIA Dipeptidyl Peptidase IV (CD26)

  • Bernhard Fleischer
  • Christiane Steeg
  • Jochen Hühn
  • Arne von Bonin
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 421)


CD26, or dipeptidyl peptidase IV, is a widely distributed cell surface glycoprotein of approximately 110 kD molecular weight. It is constitutively expressed on a variety of different cell types, particularly on epithelial cells of the intestine, prostate and kidney-proximal tubules1–3. On T cells the expression of CD26 is regulated more stringently. The molecule is absent from the majority of human resting peripheral blood T lymphocytes and is expressed weakly on a fraction of T cells in the blood. Expression increases within two days of T cell activation and increases further after culture in vitro 1. 2. It has been shown to be a suitable marker for T cells activated in vivo 4 and memory T cells have been shown to reside in the CD26+ T cell fraction5. CD26 has several unique properties that distinguish this molecule from related surface proteases:
  1. i.

    the expression of CD26 is tightly regulated in different tissues

  2. ii.

    it is associated with the differentiation and activation status of different cells

  3. iii.

    CD26 is highly conserved among different species6.



Jurkat Cell Cytoplasmic Tail Dipeptidyl Peptidase Molecular Association Dipeptidyl Aminopeptidase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fleischer, B. 1995. Dipeptidylpeptidase iV (CD26) in metabolism and the immune response. Molecular Biology Intelligence Unit. R.G. Landes Co., Austin/Springer Verlag, Berlin, 1–202.Google Scholar
  2. 2.
    Fleischer, B. 1994. CD26: a surface protease involved in T-cell activation. Immunol. Today 15:180–184.Google Scholar
  3. 3.
    Yaron, A. and N., F. 1993. Proline dependent structural and biological properties of peptides and proteins. Crit. Rev. Biochem. Mol. Biol. 28:31–81.Google Scholar
  4. 4.
    Enssle, K. H., and B. Fleischer. 1990. Absence of Epstein-Barr virus-specific, HLA class I1-restricted CD4+ cytotoxic T lymphocytes in infectious mononucleosis. Clin. Exp. Immunol. 79:409–415.Google Scholar
  5. 5.
    Hafler, D. A., D. A. Fox, and D. Benjamin. 1986. Antigen reactive memory T cells are defined by Ta I. J Immunol. 137:414–418.Google Scholar
  6. 6.
    Marduet, D., A. M. Bernard, I. Vivier, D. Darmoul, P. Naquet, and M. Pierres. 1992. cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-peptidylpeptidase IV (CD26) included in a subgroup of serine proteases. J. Biol. Chem 267:2200–2208.Google Scholar
  7. 7.
    Kameoka, J., T. Tanaka, Y. Nojima, S. F. Schlossmann, and C. Morimoto, 1993, Direct association of adenosin desaminase with a T cell activation antigen, CD26. Science 261:566–469.Google Scholar
  8. 8.
    Torimoto, Y., N. H. Dang, E. Vivier, T. Tanaka, S. F. Schlossmann, and C. Morimoto. 1991. Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes..1. Immunol, 147:2514–2517 Google Scholar
  9. 9.
    Dang, H. H., Y. Torimoto, K. Sugita, J. F. Daley, P. Schow, C, Prado, S. F. Schlossmann, and C. Morimoto. 1990. Cell surface modulation of CD26 by anti 1F7 monoclonal antibody. Analysis of surface expression and human T cell activation. J Immunol. 145:3963–3971.Google Scholar
  10. 10.
    Subramanyam, M., W. G. Gutheil, W. W. Bachovchin, and B. T. Huber. 1993. Mechanism of HIV-1 tat induced inhibition of antigen-specific T cell responsiveness. J. Immunol. 150:2544–2553.Google Scholar
  11. 11.
    Schön, E.. S. Jahn, S. T. Kiessig, H. U. Demuth, K. Neubert, A. Barth, R. von Baehr, and S. Ansorge. 1987. The role of dipeptidylpeptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and rmmunglobulin synthesis in vitro Eur J. Immunol. 171821–1826.Google Scholar
  12. 12.
    Flentke, G. R., E. Munoz, B. T. Huber, A. G. Plaut, C. A. Kenner, and Bachovchin W.W. 1991. inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc..Natl.Acud.Sci. USA 88:1556–1559.Google Scholar
  13. 13.
    Kubota, T., G. R. Flentke, W. W. Bachovchin, and B. D. Stollar. 1992. Involvement of dipeptidyl peptidase IV in an in vivo immune response. Clin. Exp. Immunol. 89:192–197.Google Scholar
  14. 14.
    Morimoto, C., Y. Torimoto, G. Levinson, C. E. Rudd, M. Schrieber, N. H. Dang, N. L. Letvin, and S. F. Schlossmann. 1989. i F7, a novel surface molecule, involved in helper function of T cells. J. Immunol 143:3430–3439.Google Scholar
  15. 15.
    Tanaka, T., Duke-Cohan, J.S., Kameoka, J., Yaron, A., Lee, I., Schlossmann, S.F., and C. Morimoto. 1994. Enhancement of antigen induced T cell proliferation by soluble CD26 (DPP-IV). Proc Natl. Acad. Sci. USA 91:3082–3086.Google Scholar
  16. 16.
    Fleischer, B. 1987. A novel pathway of human T cell activation via a 103 kD T cell activation antigen. J. bnmunol. 138:1346–1349.Google Scholar
  17. 17.
    Fleischer, B., Schendel, D., D. von Steldern. 1986. Triggering of the lethal hit in human cytotoxic T lymphocytes: a functional role for a 103 KD T cell activation antigen. Eue. J. Immunol. 16:741–746.Google Scholar
  18. 18.
    Hegen, M., G. Niedobitek, C. E. Klein, H. Stein, and B. Fleischer. 1990. The T cell triggering molecule Tp 103 is associated with dipeptidyl aminopeptidase IV activity. J. Immunol. 144:2908–2914.Google Scholar
  19. 19.
    Vivier, I., D. Marguet, P. Naquet, and e. al. 1991. Evidence that thymocyte-activating molecule is mouse CD26 (dipeptidyl peptidase IV). J. Immunol, 147:447–454.Google Scholar
  20. 20.
    Hegen, M., D. Camerini, and B. Fleischer. 1993. Function of dipeptidyl peptidase IV (CD26, Tp103) in transfected human T cells. Cell. hnmunol. 146:249–260.Google Scholar
  21. 21.
    Schrezenmeier, H., and B. Fleischer. 1988. A regulatory role for the CD4 and CDS molecules in T cell activation. J. Immunol. 141:398–403.Google Scholar
  22. 22.
    Dang, N. H., Y. Torimoto, K. Deusch, S. F. Schlossmann, and C. Morimoto. 1990. Comitogenic effect of solid phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J. Immunol. 144:4092–4100.Google Scholar
  23. 23.
    Fleischer, B., E. Sturm, J. E. de Vries, and H. Spits. 1988. Triggering of cytotoxic T lymphocytes and NK cells via Tp 103 pathway is dependent on the expression of the T cell receptor/CD3 complex. J. Immunol. 141:1103–1107.Google Scholar
  24. 24.
    Howard, F. D., P. Moingeon, U. Moebius, D. J. McConkey, B. Yandava, T. E. Gennert, and E. L. Reinherz 1992. The CD3 Ç cytoplasmic domain mediates CD2-induced T cell activation. J.Exp.Med. 176: 139–145.Google Scholar
  25. 25.
    Reth, M. 1989. Antigen receptor clue. Nature 338:383–384.Google Scholar
  26. 26.
    Samelson, L. E., M. D. Patel, A. M. Weissman, J. B. Harford, and R. D. Klausner. 1986. Antigen activation of murine T cell induces tyrosine phosphorylation of a polypeptide that is associated with the T cell antigen receptor. Cell 46:1083–1090.Google Scholar
  27. 27.
    Wegener, A. M. K., F. Letourneur, A. Hoeveler, T. Brocker, F. Luton, and B. Malissen. 1992. The T cell receptor/CD3 complex is composed of at least two autonomous transduction modules. Cell 68:83–95.Google Scholar
  28. 28.
    Donnadieu, E., A. Trautmann, M. Malissen, J. Trucy, B. Malissen, and E. Vivier. 1994. Reconstitution of CD3 S coupling to calcium mobilization via genetic complementation, J. of Biological Chemistry. 269:32828–32834.Google Scholar
  29. 29.
    Mittrücker, H. W., C. Steeg, B. Malissen, and B. Fleischer. 1995. The cytoplasmic tail of the T cell receptor chain is required for signaling via CD26. Eue J. Immunol. 25:295–297.Google Scholar
  30. 30.
    Moingeon, P., J. L. Lucich, D. J. McConkey, F. Letourneur, B. Malissen, J. Kochan, H. C. Chang, H. R. Rodewald, and E. L. Reinherz. 1992. CD3 Ç dependence of the CD2 pathway of activation in T lymphocytes and natural killer cells. Proc.Natl.Acad.Sci. USA 39:1492–1496.Google Scholar
  31. 31.
    Hegen. M., H. W. Mittrúcker, R. Hug, and B. Fleischer. 1993. Enzymatic activity of CD26 (dipeptidyl peptidase IV) is not required for its signalling function in T cells. lmmunohiol. 189:483–493.Google Scholar
  32. 32.
    Stecg, C., U. Hartwig, and B. Fleischer. 1995. Unchanged signaling capacity of mutant CD26/Dipeptidyl peptidase IV molecules devoid of enzymatic activity. Cell. Immunol. 164:311–315.Google Scholar
  33. 33.
    Tanaka, T.. J. Kameoka, A. Yaron, S. F. Schlossmann, and C. Morimoto. 1993. The costirnulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity. Proc. Natl. Acad. Scr_ USA 90:4586–4590.Google Scholar
  34. 34.
    Grabstein. K.. J. Eisenmann, D. Modizuki, P. Schanebeck, P. Cordon, T. Hopp, C. March, and S. Gilles. 1986. Purification to homogeneity of B cell stimulating factor. J. Exp. ruled. 163’1405–1414.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Bernhard Fleischer
    • 1
  • Christiane Steeg
    • 1
  • Jochen Hühn
    • 1
  • Arne von Bonin
    • 1
  1. 1.Bernhard Nocht Institute for Tropical MedicineHamburgGermany

Personalised recommendations